Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Conditions:   Alcohol Use Disorder (AUD);   Post Traumatic Stress Disorder (PTSD) Interventions:   Drug: Placebo;   Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg;   Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg;   Procedure: Ethanol Infusion;   Behavioral: PTSD Reactivity Condition;   Behavioral: Alcohol Cue R eactivity Sponsors:   Pharmacotherapies for Alcohol and Substance Abuse Consortium;   United States Department of Defense;   Congressionally Directed Medical Research Programs;   RTI International;   VA Connecticut Healthcare System;   BioXcel Therapeutics Inc;   Yale University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials